| Valentina Irene Ruzecki, MD | |
|
11102 Sunrise Blvd E, Suite 103, Puyallup, WA 98374 | |
| (253) 848-8797 | |
| (253) 845-0100 |
| Full Name | Valentina Irene Ruzecki |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 11102 Sunrise Blvd E, Puyallup, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750337150 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD00041060 (Washington) | Primary |
| Entity Name | Childrens Hospital Of The Kings Daughters Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578954590 PECOS PAC ID: 0941265284 Enrollment ID: O20150623001707 |
News Archive
The Joint West Africa Research Group began a study today designed to identify cases of suspected severe infectious disease at medical centers in West Africa. The study is being led by the U.S. Military HIV Research Program of the Walter Reed Army Institute of Research.
Every year in the United States, about 800,000 people experience a stroke. Many are left with neurological complications such as paralysis on one side of the body, speech and language problems, vision issues, behavioral changes, and memory loss.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: "Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson's Disease Biomarker" and is the second awarded to Targacept by MJFF in the last six months.
The National Institute for Health and Clinical Excellence (Nice) issued new draft guidance recommending fingolimod (brand name Gilenya) on the NHS for some patients with a form of MS. The new drug can help reduce the number of relapses in adults with highly active relapsing-remitting multiple sclerosis (RRMS), which is characterized by periods when symptoms worsen and then improve.
Angiotech Pharmaceuticals, Inc. today announced that the affected creditors of Angiotech and certain of its subsidiaries (collectively, the "Angiotech Entities") have unanimously approved the Second Amended and Restated Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities pursuant to the Companies' Creditors Arrangement Act (Canada).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Valentina Irene Ruzecki, MD 11102 Sunrise Blvd E, Suite 103, Puyallup, WA 98374 Ph: (253) 848-8797 | Valentina Irene Ruzecki, MD 11102 Sunrise Blvd E, Suite 103, Puyallup, WA 98374 Ph: (253) 848-8797 |
News Archive
The Joint West Africa Research Group began a study today designed to identify cases of suspected severe infectious disease at medical centers in West Africa. The study is being led by the U.S. Military HIV Research Program of the Walter Reed Army Institute of Research.
Every year in the United States, about 800,000 people experience a stroke. Many are left with neurological complications such as paralysis on one side of the body, speech and language problems, vision issues, behavioral changes, and memory loss.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: "Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson's Disease Biomarker" and is the second awarded to Targacept by MJFF in the last six months.
The National Institute for Health and Clinical Excellence (Nice) issued new draft guidance recommending fingolimod (brand name Gilenya) on the NHS for some patients with a form of MS. The new drug can help reduce the number of relapses in adults with highly active relapsing-remitting multiple sclerosis (RRMS), which is characterized by periods when symptoms worsen and then improve.
Angiotech Pharmaceuticals, Inc. today announced that the affected creditors of Angiotech and certain of its subsidiaries (collectively, the "Angiotech Entities") have unanimously approved the Second Amended and Restated Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities pursuant to the Companies' Creditors Arrangement Act (Canada).
› Verified 3 days ago
Mr. Michael Lane Pearson, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 12904 94th Ave East, Puyallup, WA 98373 Phone: 253-841-3999 Fax: 253-841-7311 | |
Angela A Viniarski, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1706 Meridian S, Suite 120, Puyallup, WA 98371 Phone: 253-848-8797 Fax: 253-446-3239 | |
Andrew T Sledd, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1007 39th Ave Se, Puyallup, WA 98374 Phone: 253-435-3100 Fax: 253-435-3298 | |
Dr. Victoria Devere, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1700 5th St Se, Puyallup, WA 98372 Phone: 253-848-8797 | |
Roselynn Wee Sim Cuenca, M.D., M.P.H. Pediatrics Medicare: Medicare Enrolled Practice Location: 1910 Meridian St S, Ste A, Puyallup, WA 98371 Phone: 253-848-2303 | |
Edward J Husarik, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1706 Meridian S, Suite 120, Puyallup, WA 98371 Phone: 253-848-8797 Fax: 253-446-3239 | |
Taylor Ryan Mclain, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 11102 Sunrise Blvd E Ste 103, Puyallup, WA 98374 Phone: 253-848-8797 |